Your browser is no longer supported. Please, upgrade your browser.
EyePoint Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.43 Insider Own0.73% Shs Outstand12.80M Perf Week5.51%
Market Cap165.22M Forward P/E- EPS next Y-2.13 Insider Trans22.15% Shs Float10.27M Perf Month127.50%
Income-40.30M PEG- EPS next Q-0.51 Inst Own46.60% Short Float3.40% Perf Quarter119.01%
Sales35.90M P/S4.60 EPS this Y-3.60% Inst Trans16.51% Short Ratio1.45 Perf Half Y49.38%
Book/sh0.59 P/B18.51 EPS next Y27.30% ROA-53.80% Target Price- Perf Year-36.14%
Cash/sh1.90 P/C5.76 EPS next 5Y- ROE-441.00% 52W Range3.51 - 21.00 Perf YTD65.96%
Dividend- P/FCF- EPS past 5Y-35.80% ROI- 52W High-48.00% Beta1.52
Dividend %- Quick Ratio3.40 Sales past 5Y-5.20% Gross Margin87.00% 52W Low211.02% ATR1.00
Employees84 Current Ratio3.70 Sales Q/Q528.00% Oper. Margin-93.40% RSI (14)79.53 Volatility14.37% 13.20%
OptionableYes Debt/Eq6.70 EPS Q/Q79.70% Profit Margin- Rel Volume0.73 Prev Close10.95
ShortableYes LT Debt/Eq6.68 EarningsNov 05 BMO Payout- Avg Volume239.88K Price10.92
Recom2.00 SMA2049.03% SMA5094.02% SMA20063.89% Volume175,144 Change-0.27%
Apr-06-20Downgrade B. Riley FBR Buy → Neutral $4 → $1
Nov-04-19Resumed Laidlaw Buy $5
Sep-12-19Initiated Guggenheim Buy
Jan-11-21 04:01PM  
Jan-05-21 01:36PM  
Jan-03-21 07:00PM  
Dec-18-20 07:00AM  
Dec-08-20 09:20AM  
Dec-03-20 07:00AM  
Nov-25-20 09:13AM  
Nov-19-20 07:00AM  
Nov-16-20 07:00AM  
Nov-10-20 07:00AM  
Nov-05-20 09:15AM  
Oct-29-20 12:35PM  
Oct-08-20 07:00AM  
Oct-07-20 07:00AM  
Sep-30-20 08:25AM  
Sep-10-20 07:00AM  
Aug-26-20 11:51AM  
Aug-24-20 07:00AM  
Aug-20-20 07:00AM  
Aug-05-20 09:25AM  
Aug-04-20 07:00AM  
Jul-29-20 07:00AM  
Jul-27-20 07:00AM  
Jul-13-20 07:00AM  
Jul-02-20 07:59AM  
Jun-24-20 01:01PM  
Jun-18-20 08:42AM  
May-27-20 12:50PM  
May-26-20 07:00AM  
May-18-20 07:00AM  
May-06-20 08:45AM  
Apr-29-20 08:00AM  
Apr-08-20 06:10AM  
Apr-01-20 11:35AM  
Mar-31-20 10:54AM  
Mar-23-20 11:39PM  
Mar-05-20 08:25AM  
Mar-02-20 07:00AM  
Feb-27-20 07:00AM  
Feb-21-20 09:09AM  
Feb-20-20 04:01PM  
Feb-18-20 07:00AM  
Feb-04-20 07:51AM  
Feb-03-20 05:24PM  
Jan-30-20 07:56AM  
Jan-27-20 07:00AM  
Jan-23-20 07:00AM  
Dec-22-19 05:31PM  
Dec-04-19 07:00AM  
Nov-25-19 06:46PM  
Nov-19-19 10:54AM  
Nov-14-19 07:00AM  
Nov-07-19 07:30AM  
Nov-04-19 07:00AM  
Nov-01-19 07:00AM  
Oct-31-19 10:35AM  
Oct-24-19 07:00AM  
Oct-02-19 04:05PM  
Sep-27-19 07:00AM  
Sep-26-19 07:00AM  
Sep-09-19 07:00AM  
Sep-06-19 08:32AM  
Aug-23-19 11:24AM  
Aug-07-19 07:35AM  
Jul-31-19 10:36AM  
Jul-30-19 04:15PM  
Jul-25-19 07:00AM  
Jul-24-19 07:00AM  
Jul-23-19 07:00AM  
Jul-15-19 07:00AM  
Jul-08-19 09:13AM  
Jul-01-19 07:00AM  
Jun-29-19 05:26PM  
Jun-13-19 07:00AM  
Jun-10-19 07:00AM  
May-17-19 04:39AM  
May-15-19 07:00AM  
May-08-19 07:30AM  
May-01-19 10:32AM  
Apr-23-19 07:00AM  
Apr-16-19 07:00AM  
Apr-02-19 07:00AM  
Mar-28-19 12:44PM  
Mar-27-19 04:05PM  
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elston GeorgeChief Financial OfficerSep 04Buy0.4810,0004,80040,000Sep 09 09:16 AM
Elston GeorgeChief Financial OfficerAug 24Buy0.6110,0006,11230,000Aug 26 09:21 AM
Jones David ScottSVP & Chief Commercial OfficerJun 30Option Exercise0.0041,050041,050Jul 02 06:15 PM
Paggiarino Dario A.Chief Medical OfficerJun 30Option Exercise0.0041,0500101,193Jul 02 06:14 PM
Lurker NancyPresident & CEOJun 30Option Exercise0.00124,6670784,467Jul 02 06:13 PM
Lurker NancyPresident & CEOJun 27Option Exercise0.0040,0000659,800Jun 30 07:40 PM
Paggiarino Dario A.Chief Medical OfficerJun 27Option Exercise0.0010,000063,079Jun 30 07:52 PM
Lurker NancyPresident & CEOJun 14Option Exercise0.0045,0000619,800Jun 16 05:03 PM
Paggiarino Dario A.Chief Medical OfficerJun 14Option Exercise0.0014,200057,247Jun 16 05:00 PM
Elston GeorgeChief Financial OfficerMar 12Buy0.9610,0009,60020,000Mar 13 08:41 AM
Lurker NancyPresident & CEOMar 10Buy1.0698,000104,027574,800Mar 11 08:40 AM
Lurker NancyPresident & CEOFeb 21Option Exercise0.00137,1740476,800Feb 25 04:50 PM